New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight The LAG ...

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year's ASCO conference after trial results showed their potential as next-generation ...

This discovery lays a crucial foundation for developing new LAG-3 blocking therapies, enhancing the potential of Immutep’s anti-LAG-3 small molecule program. Such advancements are pivotal for ...

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...